Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated Oct. 1, 2021:
Effective Nov. 1, 2021:
- Healthcare Administered Multiple Sclerosis (formerly IV Multiple Sclerosis)
- Multiple Sclerosis
- Hepatitis C Direct Acting Antivirals
- Injectable and Healthcare Administered Oncology
- Rituximab
- Xermelo
- Peg-interferon
- GLP-1 Agonists
- Insulin Combination
- Lupus
- Thyroid Eye Disease
- IL-4 Inhibitors
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.